ArticleBMC cancer2025

Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study.

Xiaoli Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.